MATE1 regulates cellular uptake and sensitivity to imatinib in CML patients

Although imatinib is highly effective in the treatment of chronic myeloid leukemia (CML), 25–30% patients do not respond or relapse after initial response. Imatinib uptake into targeted cells is crucial for its molecular response and clinical effectiveness. The organic cation transporter 1 (OCT1) ha...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood Cancer J
Main Authors: Harrach, S, Schmidt-Lauber, C, Pap, T, Pavenstädt, H, Schlatter, E, Schmidt, E, Berdel, W E, Schulze, U, Edemir, B, Jeromin, S, Haferlach, T, Ciarimboli, G, Bertrand, J
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2016
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5056971/
https://ncbi.nlm.nih.gov/pubmed/27635733
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bcj.2016.79
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados